Dow falls 352 points as 10-year Treasury yield tops 5.1%

source:

[1] Dow falls 350 points as 10-year Treasury yields hit 5.1% (https://invezz.com/news/2026/09/23/dow-falls- ...)[2] 10-year U.S. Treasury yield tops 5.1%, marking its highest level since 2007 (https://seekingalpha.com/news/4646208-us10y-t ...)[3] 10-year Treasury yield hits highest level since 2007 as market prices in another Fed rate hike (https://www.msn.com/en-us/news/other/10-year- ...)[4] What's the Significance of the 10-Year Treasury Yield? Here's Why It Matters to Stock and Bond Investors (https://www.msn.com/en-us/money/top-stocks/wh ...)[5] Bond Yields Soar the Most Since Trump’s Tariffs Rattled Markets (https://www.nytimes.com/2026/09/23/business/b ...)

Related News

Sep 23 2026, 21:02

Viking Therapeutics raises $400 million as VKTX dilution risk builds

Viking Therapeutics plans to sell $200.0 million of common stock alongside $200.0 million of convertible senior notes maturing in 2032, a $400.0 million dual raise that adds both new shares and new debt to a company with no marketed product. The two offerings are separate and neither is contingent on the other closing, the San Diego-based company said in a Sept. 23 statement. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are joint book-running managers on both. Each offering carries a 30-day underwriter option for an additional $30.0 million, which would lift the total to $460.0 million if fully exercised. "The completion of the common stock offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock offering," Viking said in the statement. The convertible notes are senior unsecured obligations that pay interest semiannually and mature Oct. 15, 2032. Viking can settle conversions in cash, stock, or a mix at its own election — a provision that lets the company cap share issuance if the stock rallies but leaves holders exposed to whatever mix Viking chooses. The interest rate, initial conversion rate, and conversion price will not be set until pricing. Viking may redeem the notes for cash on or after Oct. 22, 2029, but only if the stock trades above 130% of the conversion price for a specified period. A separate "cleanup" call lets Viking redeem the notes in whole if fewer than 15% of the original principal remains outstanding. ## The dilution math lands on a pre-revenue balance sheet Viking has no approved drug and no product revenue. Its lead asset, VK2735, is a dual GLP-1 and GIP receptor agonist — the same mechanism class as Eli Lilly's tirzepatide, sold as Zepbound and Mounjaro — being tested in Phase 3 obesity trials in both subcutaneous and oral formulations. The company is also advancing VK3019, an amylin receptor agonist, plus VK2809, an oral thyroid hormone receptor beta agonist, and VK0214 for X-linked adrenoleukodystrophy. That pipeline is funded entirely by capital markets. Viking did not disclose its cash balance, share count, or the resulting dilution percentage in the offering announcement, and the preliminary prospectus supplements filed with the SEC are the only place those figures will appear. The company said proceeds will fund continued clinical development, advancement, and commercialization of VK2735, continued development of VK3019, and general research, working capital, and corporate purposes. The structure matters more than the headline number. A straight $400.0 million equity sale would dilute holders immediately and permanently. Splitting the raise in half defers part of the cost: the convertible only converts if the stock clears the conversion price, so Viking pays interest instead of handing over shares if the shares stay weak. The trade-off is a debt claim sitting ahead of equity in the capital structure, plus a redemption trigger at 130% of the conversion price that effectively caps how much of a rally equity holders capture before the notes convert. ## Peers have already repriced on the same playbook Viking is not the first obesity-focused developer to tap both markets at once. The sector's clinical-stage names have leaned on convertibles repeatedly as GLP-1 competition intensified, and the pattern is consistent: the equity tranche prices at a discount to the last close, the convertible tranche prices with a conversion premium, and the stock trades lower into and after pricing. The competitive backdrop sharpens the read. Lilly and Novo Nordisk control the marketed GLP-1 market, while Amgen, Pfizer, Roche, and AstraZeneca are all funding their own obesity programs. Viking's pitch is efficacy and tolerability in a market where the incumbents already have manufacturing scale, payer relationships, and commercial infrastructure that a clinical-stage company would have to build or buy. That is precisely why the cash is needed — and precisely why the market prices the dilution before the data. For investors, the near-term question is arithmetic, not science. The offering price on the equity tranche, the conversion premium on the notes, and the updated share count in the prospectus supplement will determine the actual cost to existing holders. Until those terms price, VKTX holders are carrying an unquantified dilution overhang plus a new senior claim on the balance sheet. The science case for VK2735 is unchanged by the raise; the per-share claim on that science is not. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 20:56

S&P 500 slides as 10-year Treasury yield tops 5%

The S&P 500 fell 1.4% to 5,412 on Wednesday, its steepest one-day drop in six weeks, after the 10-year Treasury yield climbed 16 basis points to 5.12% — the first close above 5% since July 2007. The Nasdaq Composite lost 2.1% to 17,084 and the Dow Jones Industrial Average slipped 0.9% to 42,310, as traders priced in another Federal Reserve rate increase before year-end. "The 10-year at 5.12% is the whole story — it resets the discount rate on every cash flow in the index, and the longest-duration names feel it first," said Priya Mehta, head of equity market structure at Edgen Research. "Until the long end stabilizes, rallies are going to be sold into." The damage was concentrated where valuations depend most on distant earnings. Technology fell 2.6% and communication services dropped 2.2%, with consumer discretionary down 1.8%. Defensive corners held: utilities slipped 0.3%, consumer staples lost 0.4% and energy added 0.2% as Brent crude rose 1.1% to $94.60 a barrel. Roughly 3,900 New York Stock Exchange issues declined against 1,100 that advanced, and composite volume ran about 18% above the 20-day average. The VIX jumped 2.4 points to 21.6, its highest since August and above its one-year median of 17.4. The move began in the bond market. Yields rose across the curve as investors sold Treasuries, with the 30-year climbing 14 basis points to 5.28% and the two-year up 9 basis points to 5.06%, flattening the 2s10s spread to 6 basis points. The dollar strengthened alongside the selloff, with the DXY index up 0.6% to 107.4, while gold fell 0.8% to $2,612 an ounce as higher real rates raised the opportunity cost of holding bullion. Traders pointed to three catalysts: a run of firm economic data that pushed back the timing of Fed cuts, heavy Treasury supply as the deficit widens, and a repricing of the terminal rate above 5.5% in futures markets. Fed funds futures now assign a 46% probability to another quarter-point increase at the November meeting, up from 28% a week earlier, according to CME Group data. ## Rate-Sensitive Names Take the Brunt The rotation was visible beneath the index level. Regional banks fell 3.1% as the gap between deposit costs and loan yields narrowed, and homebuilders dropped 4.2% with the average 30-year mortgage rate near 7.9%. Real estate investment trusts lost 2.8%. Utilities' relative resilience reflected their regulated, bond-like cash flows rather than any improvement in demand. Small caps underperformed sharply, with the Russell 2000 down 2.4% to 2,148, because smaller companies carry a higher share of floating-rate debt. The equal-weighted S&P 500 fell 1.1%, less than the cap-weighted index, confirming that the largest technology names drove the decline. ## What a Sustained 5% Yield Means A 10-year yield held above 5% compresses equity multiples mechanically. At a 5.12% risk-free rate, the S&P 500's forward earnings yield of roughly 5.4% leaves an equity risk premium near 0.3 percentage point, close to the narrowest since 2002. That gap has historically preceded either a decline in bond yields or a de-rating in stock prices. The next test comes on Nov. 7, when the Fed announces its rate decision, followed by the October consumer price index on Nov. 13. A core reading above 0.3% month over month would likely push the 10-year toward 5.25%, a level last seen in June 2007. Corporate borrowers are already adjusting: investment-grade spreads widened 4 basis points to 112 basis points, and the pace of new high-yield issuance slowed to $2.1 billion this week from a $6.8 billion weekly average this year. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 20:42

Anthropic slows frontier R&D as 2 states push AI kill switches

Frontier model training at Anthropic is about to get slower on purpose. Speaking from the UN Security Council podium, CEO Dario Amodei said the company will hold back the pace of its AI research and development for safety reasons — a pledge that lands as California moves to embed independent auditors inside AI labs and mandate a shutdown mechanism for rogue models. Anthropic did not disclose how much it intends to cut from its training roadmap, nor which model generations are affected. "Because of safety, the company will slow down the pace of AI research and development," Amodei said, adding that mismanaged AI "could pose an existential risk to all of humanity" and that he supports global efforts to stop AI being used in chemical and biological weapons. The disclosure is the first time a leading frontier lab has put a deceleration on the record at a multilateral forum. Anthropic competes directly with OpenAI, Google DeepMind and Meta Platforms in training runs that routinely consume tens of thousands of accelerators; the company has not published a training cost for its current flagship, Claude, and has not said whether the slowdown changes previously stated compute commitments. California has already built the enforcement scaffolding Amodei is asking for at the global level. Governor Gavin Newsom signed SB 813 in 2026, making the state the first to certify independent verification organizations with demonstrated independence from AI companies, and AB 1405, which created a state registry for AI auditors with standards for their independence, transparency and integrity. A separate executive order directs the Government Operations Agency to accelerate both timelines and to convene national experts on requiring frontier developers to embed a designated verification organization onsite for regular audits, to have safety frameworks and risk assessments verified to independent standards, and to develop a "kill switch" for frontier models whose efficacy is verified on an ongoing basis. The advisory group Newsom named includes Gillian Hadfield of Johns Hopkins University, Alondra Nelson of the Institute for Advanced Study, Rob Reich of Stanford University and Jason Goldman of the Center for Shared AI Prosperity. "Governor Newsom's executive order addresses the hardest questions in AI safety governance, including who verifies a frontier lab's safety claims and whether a model can be reliably shut down," Goldman said. ## Certification is the revenue question, not the ethics question Amodei's call for an AI safety certification system and global standards is the part with a balance sheet attached. A certification regime creates a compliance market — third-party evaluators, audit tooling, incident reporting — and simultaneously raises the fixed cost of shipping a frontier model. That cost falls hardest on labs without Anthropic's or Google's balance sheet, and it is the mechanism by which a voluntary slowdown becomes an industry-wide one. The precedent is already visible in the state framework. SB 53, the Transparency in Frontier Artificial Intelligence Act signed in 2025, requires frontier developers to publish safety frameworks, report specified critical safety incidents to the state and protect whistleblowers. Newsom's order also directs an update to the definition of critical safety incidents to include loss-of-control events such as the Hugging Face attack. No federal law requires AI companies to report dangerous incidents, and the order calls on Congress to adopt the state framework as a floor. For investors, the read-through splits by layer. Frontier model developers face higher compliance and evaluation costs and a slower capability cadence. Accelerator suppliers — Nvidia, AMD and Broadcom — carry the demand sensitivity, since any broad deceleration in training-run scale hits data center order books before it hits model release schedules. Compliance, audit and AI security vendors are the offsetting trade. Anthropic is private, so there is no direct equity expression; the closest listed proxies are the hyperscalers that fund it and the chipmakers that supply it. ## A bioweapons warning and an enzyme discovery in the same speech Amodei's security framing was explicit: he said there is a risk that bad actors use AI to build biological weapons, and that he supports global efforts to prevent AI use in chemical and biological weapons. That argument is the political engine behind certification — it converts AI governance from a consumer-protection issue into a national-security one, which is the category of regulation that historically moves fastest. The same speech carried the counter-argument. Anthropic said it is establishing a life-sciences research laboratory, and that its Claude model discovered a novel enzyme system containing CRISPR-like DNA repeat sequences. CRISPR-based gene editing, the technology the discovery echoes, underpins a gene-editing market that has produced approved therapies from CRISPR Therapeutics and Intellia Therapeutics. Anthropic did not disclose the enzyme's function, the validation methodology or whether the finding has been peer-reviewed. That gap matters for how the slowdown should be read. A model that surfaces a previously unknown biological system is evidence that capability is still advancing on the science side even as the company throttles the training side — and it is the strongest argument against the assumption that a self-imposed pause at one lab meaningfully changes the aggregate rate of progress. OpenAI, Google DeepMind and Meta have published no matching commitment. The next checkpoint is California's implementation timeline for SB 813 and AB 1405, which the executive order directs the Government Operations Agency to accelerate, alongside the expert group's recommendations on onsite verification and kill-switch standards. Whether rival labs adopt comparable cadence commitments — or wait for certification to be imposed on them — is the variable that determines whether Amodei's UN remarks mark a turning point or a single company's positioning. This article is for informational purposes only and does not constitute investment advice.